Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance  by Fantin, Valeria R. et al.
A R T I C L EAttenuation of LDH-A expression uncovers a link between
glycolysis, mitochondrial physiology, and tumor maintenance
Valeria R. Fantin,1,3,4 Julie St-Pierre,2,3,5 and Philip Leder1,*
1 Department of Genetics, Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts 02115
2 Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115
3 These authors contributed equally to this work.
4 Present address: Merck & Co., Inc., Boston, Massachusetts 02115.
5 Present address: Institut de Recherche en Immunologie et en Cance´rologie (IRIC), Universite´ de Montre´al Pavillon Marcelle-Coutu,
Montre´al, Que´bec, Canada H3T 1J4.
*Correspondence: leder@genetics.med.harvard.edu
Summary
Alterations in cellular metabolism are among the most consistent hallmarks of cancer. Herein we have investigated the re-
lationship between increased aerobic lactate production andmitochondrial physiology in tumor cells. To diminish the ability
of malignant cells tometabolize pyruvate to lactate, lactate dehydrogenase A (LDH-A) levels were knocked down bymeans of
LDH-A short hairpin RNAs. Reduction in LDH-A activity resulted in stimulation of mitochondrial respiration and decrease of
mitochondrial membrane potential. It also compromised the ability of these tumor cells to proliferate under hypoxia. The
tumorigenicity of the LDH-A-deficient cells was severely diminished, and this phenotype was reversed by complementation
with the human ortholog LDH-A protein. These results demonstrate that LDH-A plays a key role in tumor maintenance.Introduction
A distinctive feature of tumor cells is the alteration of their carbo-
hydrate metabolism. In general, normal cells produce most
of the ATP from glucose through oxidative phosphorylation
(OXPHOS) (Rolfe and Brown, 1997). On the other hand, many
cancer cells produce ATP by conversion of glucose to lactate
and exhibit lower OXPHOS activity. The ability of malignant cells
to produce large amounts of lactic acid was recognized by War-
burg in the early 20s (Warburg, 1930). A high rate of conversion
of glucose to lactate is coupled to a high rate of glucose uptake
and glucose phosphorylation and occurs even in the presence
of normal oxygen pressure (Gatenby and Gillies, 2004; Mathu-
pala et al., 1997). The ‘‘glycolytic phenotype’’ appears to confer
emerging malignant cells with a selective advantage, which may
help to explain in part why this metabolic strategy is commonly
observed across tumors. Accelerated glycolysis ensures ATP
levels compatible with the demands of fast proliferating tumor
cells in a hypoxic environment. Along with increased glutaminol-
ysis, it provides a constant supply of metabolic intermediates
that are essential for macromolecule biosynthesis and neces-
sary for cell growth and division (Mazurek and Eigenbrodt,CANCER CELL 9, 425–434, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.102003). In addition, the increased glucose uptake could play
a role in protection from apoptosis by rendering tumor cells
independent of growth factors (Plas and Thompson, 2002).
Because reactive oxygen species are natural by-products of mi-
tochondrial respiration, it has been proposed that glucose to
lactate conversion may protect cancer cells from oxidative
stress (Brand and Hermfisse, 1997).
The molecular basis for the increased rate of glycolysis in can-
cer cells remained elusive until the 90s. However, it has become
clear in recent years that one of the transcriptional programs
turned on by oncogenes including Ras, Src, and HER-2/Neu
through the stabilization of HIF-1a protein leads to upregulation
of most of the enzymes of the glycolytic pathway, as well as the
NADH-dependent enzyme that catalyzes the conversion of
pyruvate to lactate, lactate dehydrogenase A (LDH-A), and the
glucose transporters GLUT-1 and GLUT-3 (Dang and Semenza,
1999; Semenza et al., 2001). In addition, c-Myc has also been
shown to regulate LDH-A at the transcriptional level (Shim
et al., 1997).
Alterations in mitochondrial physiology, in addition to de-
creasing OXPHOS capacity, have also been linked to malignant
transformation (Capuano et al., 1997; Dorward et al., 1997).S I G N I F I C A N C E
The near-universal glycolytic switch of cancer cells has beenproposed to be an essential tumor trait and a consequence of the cellular
adaptation to hypoxia. Our results are consistent with a functional connection between alterations in glucose metabolism and mito-
chondrial physiology in cancer. The data also reflect that the dependency of tumor cells on glucose metabolism is a liability for these
cells under limited-oxygen conditions. Interfering with LDH-A activity as a means of blocking pyruvate to lactate conversion could be
exploited therapeutically. Because individuals with complete deficiency of LDH-A do not show any symptoms under ordinary circum-
stances, the genetic data suggest that inhibition of LDH-A activity may represent a relatively nontoxic approach to interfere with tumor
growth.16/j.ccr.2006.04.023 425
A R T I C L EHigher mitochondrial membrane potential (Dcm) has been ob-
served in a variety of carcinomas (Chen, 1988), and in cases
of chemically induced and oncogene-induced malignant trans-
formation in a variety of cell types (Liang et al., 1999; Zarbl
et al., 1987). In the case of colon cells, the transition to the neo-
plastic state has been correlated with an increase in this mito-
chondrial parameter (Heerdt et al., 2003). We have previously
described the identification of a small molecule, F16, that is
selectively toxic to carcinoma cell lines with higher than normal
Dcm (Fantin et al., 2002). The fact that glycolysis and mitochon-
drial respiration are tightly coupled processes led us to propose
that the correlative high mitochondrial membrane potential and
the susceptibility to the lipophilic cation F16 could be related to
the lower OXPHOS activity in transformed cells.
To gain some understanding about the dependency of tumor
growth on the glycolytic phenotype and the interplay between
glycolysis and mitochondrial metabolism, we decided to evalu-
ate the effect of blocking glucose to lactate conversion. To this
end, we stably knocked down LDH-A in neu-initiated mammary
tumor cells that display high glucose dependency, high LDH-A
activity, elevated mitochondrial membrane potential, and sensi-
tivity to F16. Our results show that suppressing aerobic lactate
production directly impacts mitochondrial respiration. Cells
with decreased LDH-A activity showed an increase in oxygen
consumption and OXPHOS activity. The Dcm was significantly
lower in the knockdown clones, and the accumulation of F16
in the organelles of these cells was markedly diminished. In ad-
dition, the tumorigenic potential of the malignant cells was
severely compromised by LDH-A knockdown. Ectopic expres-
sion of human LDH-A restored the glycolytic capacity of the
LDH-A knockdown cells, and this event was sufficient to reverse
the phenotypes observed in vitro and in vivo. Altogether, the
results indicate that alterations in glucose metabolism in trans-
formed cells are tied to a reorganization of mitochondrial phys-
iology. Furthermore, the data are consistent with the role of
LDH-A as an essential tumor maintenance gene and provide fur-
ther support to the concept of inhibition of glucose metabolism
as an attractive antitumor strategy.
Results
Isolation of tumor cell lines with stable
knockdown of LDH-A
Sensitivity to glucose deprivation as well as elevated LDH-A ac-
tivity has been well documented in a variety of human breast
cancer cell lines and tissue sections, respectively (Aft et al.,
2002; Balinsky et al., 1983). The glucose dependency and
LDH-A activity are shown for neu-initiated mammary epithelial
tumor cell lines in which a higher than normal Dcm has been pre-
viously observed (Figures 1A and 1B). In comparison to immor-
talized, nontransformed mouse mammary epithelial EpH4,
HC11, and NMuMg cells, all neu-initiated tumor cell lines were
extremely sensitive to treatment with the anti-metabolite 2-
deoxy-D-glucose, a well-characterized glucose antagonist,
and displayed elevated LDH-A activity. Expression of short
hairpin RNAs (shRNAs) complementary to LDH-A was used to
stably suppress expression of the enzyme. Recombinant vec-
tors containing oligonucleotide sequences encoding three
shRNAs (L1, L2, and L3) under the U6 promoter were trans-
fected into the neu-initiated tumor cells. We focused our efforts
on Neu4145 and NF980 cell lines. These cells did not undergo426apoptosis upon transient transfection of shRNA-expressing
vectors. A series of stable clones with varying degrees of ex-
pression of LDH-A protein were isolated (Figure 1C). As previ-
ously reported for tumor cells, the expression of LDH-B protein
was low in Neu4145 cells and was not affected in the derived
knockdown cells (data not shown). The highest level of suppres-
sion of LDH-A protein was achieved by L2 and L1 hairpins. The
knockdown was functionally assessed by LDH enzymatic assay
(Figure 1D). There was good correlation between the LDH-A
activity and LDH-A protein levels in the cell lines analyzed.
Clones L2-5 and L2-10 showed a 69% and 75% reduction of
LDH-A protein, and 60% to 70% reduction in enzyme activity,
respectively.
LDH-A suppression affects growth properties
of neu-initiated tumor cells
We next characterized the growth properties of parental and
LDH-A knockdown clones under normal and limiting oxygen
pressure (Figure 2). Under normoxic conditions, the rate of pro-
liferation of cells with decreased LDH-A protein was retarded
(Figure 2A). These observations showed the reliance of tumor
cells on glycolysis under normal oxygen conditions. Unlike the
parental Neu4145, growth of LDH-A-deficient tumor cells was
severely affected under hypoxic conditions (0.5% oxygen)
(Figure 2B). After 3 days from plating, the rates of proliferation
of parental cells and their derivatives with decreased LDH-A
activity differed by about 100-fold. To determine if the growth
defect observed was a consequence of the inability of LDH-A-
deficient neu-initiated tumor cells to metabolize glucose to lac-
tate, the cDNA corresponding to human LDH-A was introduced
into L2-5 cells (Figure 2C). As shown for clone L2-5.c15, ectopic
expression of LDH-A restored the rate of proliferation under nor-
mal or low oxygen pressure conditions (Figures 2A and 2B).
These results confirm the specificity of the LDH-A knockdown
approach and ruled out off-target effects as responsible for
the proliferation defect. The data are also in agreement with pre-
vious work that established an essential role for LDH-A in sup-
porting anchorage-independent growth of c-Myc-transformed
cells (Shim et al., 1997). To determine the impact of LDH-A
knockdown on the cellular energy balance, ATP levels were
measured under normal and low oxygen conditions (Figure 2D).
In comparison to parental Neu4145 cells, a modest decrease
(16%) in the ATP pool was detected in LDH-A-deficient L2-5
cells under normal pO2. On the other hand, ATP levels were sig-
nificantly lower (51%) in clones L2-5 and L2-10 under hypoxia
(Figure 2D). Similar results were observed with NF980 tumor
cells as well as derived LDH-A-deficient clones (Figures S1A–
S1C in the Supplemental Data available with this article online).
The inability of cells with decreased LDH-A activity to sustain
high ATP levels most likely explains the block in proliferation
under conditions of oxygen deprivation. The effect of LDH-A
knockdown on the proliferation of immortalized, nontrans-
formed mouse mammary epithelial EpH4 cells (Lopez-Barahona
et al., 1995; Reichmann et al., 1989, 1992) was also monitored
(Figure 2E). The EpH4 cells are fully polarized, nontumorigenic
in nude mice, and capable of forming 3D tubular structures
when grown in collagen gels, reminiscent of normal luminal ep-
ithelial cells (Fialka et al., 1996; Oft et al., 1996). The growth of
both EpH4 and LDH-A-deficient subclone EpH4.L2-13 was in-
distinguishable under normal pO2. Neither EpH4.L2-13 nor the
parental EpH4 cells proliferated under hypoxia, in contrast toCANCER CELL JUNE 2006
A R T I C L EFigure 1. Characterization of glucose depen-
dency and LDH-A activity of mouse mammary
tumor cell lines
A: Neu-initiated tumor cell lines as well as immor-
talized nontransformed EpH4 and NMuMg cells
were grown in the presence of increasing
amounts of the glucose anti-metabolite 2-de-
oxy-D-glucose as indicated for 48 hr. Proliferation
was assessed by BrdU-incorporation assay de-
scribed under Experimental Procedures. Results
were expressed as average percent 6 SEM of
vehicle-treated control.
B: Comparison of LDH-A activity across a panel
of normal and tumor mouse mammary epithelial
cell lines. The results represent the average 6
SEM of three independent experiments.
C: Western blot analysis was performed on
whole-cell lysates prepared from Neu4145 cells
and selected clones stably expressing shRNAs
for LDH-A. Samples were probed with goat poly-
clonal anti-LDH (top panel) and mouse mono-
clonal anti-LDH-A (middle panel). Membranes
were reprobed with anti-b-actin as a loading
control (bottom panel).
D: LDH-A activity in knockdown clones, ex-
pressed as percent of enzyme activity in paren-
tal Neu4145 cells.the hypoxia tolerance of the tumor cell lines Neu4145 and
NF980. Similar results were obtained in studies with nontrans-
formed mammary epithelial HC11 cells (Figure S1D). This differ-
ence reflects the OXPHOS reliance of these nonmalignant lines
and highlights the metabolic adaptation of malignant ones. Alto-
gether, the results demonstrate that tumor cells rely on LDH-A
activity even when oxygen is not limiting, and that endurance
of tumor cells in a hypoxic environment is highly dependent on
LDH-A activity.
Mitochondrial activity in tumor cells is affected
by LDH-A knockdown
As mentioned earlier, we had reported the identification of F16,
a delocalized lipophilic cation that is selectively toxic to carci-
noma cells with elevated Dcm. Mitochondrial membrane and
plasma membrane hyperpolarization, the basis for the selectiv-
ity of F16 for carcinoma cells, have been described for a variety
of malignant cells. However, to date there is no clear under-
standing for the basis of this phenomenon. Tumor cells in gen-
eral exhibit reduced OXPHOS activity (Capuano et al., 1997;
Cuezva et al., 2002; Isidoro et al., 2004). We and others have
proposed that the increased rate of aerobic lactate production,
the lower OXPHOS activity, and the elevated Dcm commonly
observed in transformed cells could be interrelated phenomena.
In principle, the inability of tumor cells to use mitochondria to
meet their energetic demand, which coincides with dissipation
of a smaller fraction of the mitochondrial proton gradient
(DmH+) normally used to produce ATP, may contribute to the
elevated mitochondrial membrane potential (Dcm) observed in
a variety of carcinoma cells. We reasoned that the inherently
highly glycolytic Neu4145 cells, and derived clones with de-
creased LDH-A activity, could provide the perfect setting to
test this model. We compared F16 accumulation, mitochondrial
membrane potential, and respiration rate in Neu4145 cells and
LDH-A knockdown clones. First, cells were incubated in me-
dium containing 3 mM F16 (Figure 3A). In contrast to Neu4145
cells, no significant build-up of F16 in the mitochondriaCANCER CELL JUNE 2006compartment was observed in LDH-A-deficient L2-5 and
L2-10 cells. On the other hand, LDH-A complementation re-
stored the ability of cells to accumulate F16 as depicted by clone
L2-5.c15. The reduced accumulation of F16 in cells with LDH-A
knockdown was confirmed by semiquantitative flow cytometric
analysis (Table 1). No differences in mitochondrial morphology
or mitochondrial volume density were observed by electron mi-
croscopy analysis of glutaraldehyde-fixed cells (Figure 3B). The
mitochondrial mass across these cell lines was comparable as
assessed by analysis of cells incubated with the mitochondrial
cardiolipin dye nonyl-acridine orange (Table 1).
Next, to gain a clear insight into the adaptation of mitochon-
drial metabolism upon LDH-A knockdown, we performed a de-
tailed bioenergetics analysis of mitochondrial functions in the
four experimental cell lines described above. The rate of respira-
tion was assessed by the measurement of oxygen consumption
using a Clark-type electrode. First, it is important to appreciate
that mitochondrial respiration consists of coupled and un-
coupled respiration. Coupled respiration represents the fraction
of mitochondrial respiration that is used for ATP production,
while uncoupled respiration represents the fraction of mitochon-
drial respiration that is used to drive a futile cycle of protons
across the biological membrane, called proton leak. The mito-
chondrial metabolic organization of cells represents the fraction
of mitochondrial respiration that is used to drive proton leak and
ATP turnover. On average, animals spend as much as 20% of
their basal mitochondrial respiration to drive proton leak (Rolfe
and Brown, 1997), and the remaining 80% is used for ATP turn-
over. Many physiological functions have been proposed for
proton leak, but the two most prominent ones are for heat pro-
duction and protection against reactive oxygen species. Reduc-
tion of LDH-A levels in the L2-5 and L2-10 clones resulted in an
increase in total mitochondrial respiration compared with
Neu4145 control cells (Figure 4A). The complementation of the
L2-5 clone with LDH-A reduced the total mitochondrial respira-
tion back to control levels. This increase in total mitochondrial
respiration in the L2-5 and L2-10 clones was reflected in both427
A R T I C L EATP turnover (Figure 4B) and proton leak (Figure 4C). Indeed, the
L2-5 and L2-10 clones displayed higher proton leak and ATP
turnover than Neu4145 control cells. Again, the L2-5 comple-
mented clone had low rates of proton leak and ATP turnover,
similar to controls. Since the fold increase in proton leak and
ATP turnover is similar in the two LDH-A knockdown clones,
Figure 2. Effect of LDH-A knockdown on growth properties of tumor cells
in vitro
A: Proliferation curve for parental Neu4145 tumor cells (control) and LDH-A-
deficient clones L2-5 and L2-10 grown under normal oxygen pressure.
B: Proliferation curve for cells grown under hypoxic conditions. Ectopic ex-
pression of human LDH-A restores the ability of L2-5 clone to endure hypoxia.
C: Western blot analysis was performed on whole-cell lysates prepared from
parental cells (Neu 4145), LDH-A-deficient cells (clone L2-5), and LDH-A-
complemented cells (clone L2-5.c15) as described under Experimental Pro-
cedures. Equivalent amounts of proteins were immunoblotted with anti-
LDH-A and b-actin as loading control.
D:Quantification of ATP levels in cells grown under normoxic (gray bars) and
hypoxic (black bars) conditions for 48 hr using a luciferin-luciferase-based
assay. Results represent the average 6 SEM of three experiments.
E: Proliferation curve for immortalized, nontransformed EpH-4 cells and LDH-
A-deficient cells (clone L2-13) under normal oxygen pressure and hypoxic
conditions.
Results in A, B, and E represent the average 6 SEM of two independent
experiments.428the metabolic organization of all four clones was similar
(Figure 4D). Indeed, each clone devoted around 25% of its total
mitochondrial respiration for proton leak and 75% for ATP turn-
over. The decrease in F16 accumulation and increase in respira-
tion rate observed in L2-5 and L2-10 clones suggested that
reduction in LDH-A activity is accompanied with a reduction in
Dcm. To show conclusively that knockdown of LDH-A is associ-
ated with a reducedDcm, we measured this parameter quantita-
tively using [3H]triphenylmethylphosphonium (TPMP). In com-
parison to Neu4145 control cells, LDH-A knockdown L2-5 and
L2-10 clones displayed lower Dcm (Table 2). Importantly, the
L2-5.c15 clone complemented with LDH-A showed a mitochon-
drial membrane potential almost identical to that of Neu4145
cells.
One of the factors that affect the rate of respiration is NADH
levels. Since the LDH-A-catalyzed conversion of pyruvate into
lactate consumes NADH and regenerates NAD+, next we inves-
tigated the cellular levels of both pyridine nucleotides. The ratio
of free NADH/NAD+ in the cytosol was estimated from the con-
centrations of pyruvate and lactate considered to be in near
equilibrium with the couple. A 2-fold increase in the NADH/
NAD+ was measured in the L2-5 and L2-10 clones deficient in
LDH-A (Table 2). The modest but reproducible difference indi-
cated that LDH-A knockdown resulted in a perturbation in the
cytosolic NADH and NAD+ pools.
In conclusion, reduction of LDH-A levels resulted in increased
cytosolic NADH/NAD+, consistent with the increased respiration
rate and elevated mitochondrial membrane potential. In addi-
tion, the metabolic organization of the Neu4145 control cells
and knockdown clones were similar, an indication of the organ-
elle’s ability to respond both to substrate availability and cellular
energetic demand and adapt its metabolic activity.
LDH-A suppression interferes with tumorigenicity
of malignant cells
Downregulation of LDH-A activity had a profound impact on mi-
tochondria bioenergetics and interfered with proliferation of
Neu4145 tumor cells in culture. The well-established reliance
of cancer cells on the glycolytic pathway, characterized by the
increased production of lactate, may indicate that the high
ATP demand of cancer cells cannot be solely fuelled by mito-
chondrial metabolism and/or that mitochondrial metabolism is
somehow defective. It has been observed that in rodents
LDH-A increases during mammary gland tumorigenesis (Ri-
chards and Hilf, 1972). LDH-A protein expression is higher in
human breast tumor tissue compared to normal tissue, and in
lung cancer LDH-A overexpression is a negative prognostic
marker (Balinsky et al., 1983; Hilf et al., 1976; Koukourakis et al.,
2003). These findings prompted us to address the role of LDH-A
in tumorigenesis. We asked whether LDH-A knockdown that
forced tumor cells to rely exclusively on ATP supplied by mito-
chondrial OXPHOS could affect their tumorigenic capacity. To
this end, Neu4145 tumor cells and derived LDH-A knockdown
clones were orthotopically transplanted into mammary gland
fat pads of 6- to 8-week-old female mice, and tumor growth
was monitored thereafter. The fact that the Neu4145 cell line
was established from a mammary gland tumor excised from
a neu-transgenic FVB female mouse enabled syngeneic trans-
plantation of these cells as well as derived clones. The parental
Neu4145 tumor cell line, LDH-A-deficient L2-5 cells, and LDH-
A-complemented L2-5.c15 cells were injected into the fourthCANCER CELL JUNE 2006
A R T I C L EFigure 3. Effect of LDH-A knockdown on mitochondrial accumulation of the lipophilic cation
A: Cells were incubated with F16 as indicated under Experimental Procedures prior to imaging. Fluorescent F16 signal (top row) and DNA (bottom row). Scale
bars, 50 mm.
B: Images of mitochondria obtained by electron microscopy from ultrathin cryosection prepared from parental Neu4145 and derived clones. Scale bars,
200 nm.gland of female mice, and the three cohorts established were
monitored weekly. Palpable tumors were evident 1 week after
Neu4145 cell transplant. As depicted by the Kaplan-Meier sur-
vival plot, the first mouse bearing Neu4145-initiated tumors
succumbed 42 days postinjection, at which point the average
tumor volume for the cohort surpassed 1500 mm3 (Figures 5A
and 5B). By day 73 from initiation of the experiment, the com-
plete cohort had passed. The median survival for the group
with Neu4145-derived tumors was 58 days, that for the group
with L2-5.c15-derived tumors was 64 days, and that for the
group with L2-5-derived tumors was 162 days. The onset of tu-
mor appearance and kinetics of tumor growth in the L2-5.c15
transplanted cohort was indistinguishable from that of the
Neu4145-initiated group. In contrast, palpable nodules were
not identified until 5 weeks postinjection in the L2-5-trans-
planted mice. The growth rate of these tumors was remarkably
low when compared to that of Neu4145 and L2-5.c15 tumors.
By 12 weeks postinjection, divergence in the tumor growth
rate for two mice within the group became noticeable. The first
Table 1. Comparison of F16 accumulation and NAO staining by flow
cytometry
Cell line
F16 accumulation:
log F16 emission (a.u.)
Mitochondrial mass: NAO ratio,
630 nm/530 nm
Neu4145 218 6 15.2 2.44
L2-5 45 6 2.9 2.65
L2-10 52 6 3.8 2.53
L2-5.c15 196 6 8.3 2.39CANCER CELL JUNE 2006mouse within this cohort died 112 days after cell transplant. A
second mouse died at day 129. The experiment was terminated
4 months after initiation, at which point 80% of the L2-5.c15 co-
hort was still alive. Similar observations were made with a small
cohort of mice bearing tumors derived from the NF980 tumor
cell line and LDH-A-deficient subclone (Figures S2 and S3). In
all cases, tumors were removed at necropsy and subjected to
histologic examination. To assess proliferation, tumor sections
were examined for the expression of the mitotic marker Ki67
(Figure 5C). A similar average in the number of Ki67-positive
cells/100 tumor cells was observed for Neu4145 and LDH-A-
complemented L2-5.c15-derived tumors (16% 6 2.2% and
17.4% 6 2.0%, respectively). In contrast, the number of cells
positive for Ki67 (1.3% 6 0.9%) was markedly reduced in L2-5
derived tumors (p < 0.03), consistent with the slow growth of
these tumors. In addition, the pockets of necrotic and scar tis-
sue present in these small tumors were only comparable to
those observed in the oversized Neu4145-derived tumors (Fig-
ure 6A). Tumors excised 3 weeks after injection of Neu4145
cells, with comparable size to those of L2-5-initiated tumors
14 weeks postinjection were primarily comprised of proliferating
cells, indicating the inability of LDH-A knockdown cells to
endure the tumor microenvironment and grow beyond small
lesions. Western Blot analysis to examine LDH-A levels was per-
formed on lysates prepared from the isolated tumors (Figure 6B).
Whole-cell lysates were prepared from cell suspensions en-
riched for neu-initiated tumor cells following fractionation, to
minimize the contribution of nontumor cell types present in the
samples. LDH-A expression was homogenously low among429
A R T I C L EFigure 4. Bioenergetic analysis of Neu4145 pa-
rental tumor cells, derived LDH-A-deficient L2-5
and L2-10 clones, and LDH-A-complemented
L2-5.c15 clone
A: Total mitochondrial respiration consists of ATP
turnover and proton leak.
B: ATP turnover represents the respiration that
is sensitive to the inhibitor of the ATP synthase,
oligomycin.
C: Proton leak represents the respiration that is
insensitive to oligomycin.
D: Metabolic organization is the fraction of mito-
chondrial respiration that is used for ATP turnover
(black bars) and proton leak (gray bars).
The experimental conditions are defined in Ex-
perimental Procedures. Results are expressed
as average 6 SEM. Statistical significance is indi-
cated with an asterisk (p% 0.05). Data were sub-
jected to one-way ANOVA and a posteriori
Tukey test.tumors in the L2-5 group with the exception of samples pre-
pared from the two outlier animals within the cohort. It is likely
that silencing of the U6 promoter driving the expression of the
shRNA could account for the restoration of LDH-A levels in
these tumors. But regardless of the mechanism for restoration
of LDH-A expression in these tumors, these results further link
LDH-A expression with tumor proliferation and emphasize the
essential role of glycolysis for malignant growth.
Discussion
In the present study, we asked whether the high rate of glycoly-
sis was an essential tumor phenotype and whether there was
a link between this phenomenon and the widely described alter-
ations in mitochondrial metabolism in tumor cells. To this end,
we utilized shRNAs to downregulate the expression of LDH-A
in neu-initiated mammary tumor cells, and to interfere with the
ability of cells to convert glucose-derived pyruvate into lactate.
Our results show that this shift in metabolic strategy upon
LDH-A knockdown had a drastic impact on tumor physiology.
The data also provide evidence that indeed the alterations in
mitochondrial membrane potential are a consequence of the
‘‘glycolytic phenotype’’ essential for tumor growth.
Although the conversion of pyruvate into lactate occurs in nor-
mal cells in hypoxic conditions, tumor cells produce copious
amounts of lactate even when oxygen is not a limiting factor. It
has been proposed that this phenotype results from the adapta-
tion of premalignant lesions to intermittent hypoxia (Gatenby
and Gillies, 2004). However, the molecular mechanisms leading
to the increased rate of glycolysis are only partially understood.
Table 2. Mitochondrial membrane potential and NADH/NAD+ of parental
Neu4145 tumor cells and derived clones
Cell line
Mitochondrial membrane
potential (mV) Free NADH/NAD+
Neu4145 209.2 6 2.5 3.7 3 1023
L2-5 185.5 6 2.9 5.8 3 1023
L2-10 178.2 6 2.4 5.5 3 1023
L2-5.c15 207.1 6 2.4 3.2 3 1023430Our results show that limiting the LDH-A activity of several tumor
cell lines is sufficient to stimulate OXPHOS in these cells, evi-
dence of the direct link between these two processes. It is
important to emphasize though that the reversion from a highly
glycolytic metabolism to an OXPHOS-based metabolism was
only achieved by a subset of the tumor cell lines studied.
Some tumor cells had a strict LDH-A requirement. Because
tumors arise through a Darwinian evolutionary process, the se-
lected glycolytic phenotype could emerge as a consequence of
one or multiple reversible and/or irreversible adaptations that
confer a growth advantage. It is likely that the oxidative phos-
phorylation capacity of some of these tumor cell lines had
been irreversibly diminished as previously described (Capuano
et al., 1997; Cuezva et al., 2002; Isidoro et al., 2004).
In comparison to parental tumor cells, those clones with de-
creased LDH-A activity that are still capable of proliferating un-
der normoxia exhibited a severe growth defect under hypoxic
conditions in vitro. Previous work has shown that overexpres-
sion of LDH-A alone is not sufficient to induce malignant trans-
formation (Lewis et al., 2000). However, the LDH-A dependency
of Myc-transformed cells for in vitro proliferation under anaero-
bic conditions as well as for soft agar clonogenicity has been
clearly established (Shim et al., 1997). Our results showed that
LDH-A deficiency significantly compromised the tumorigenic
potential of neu-initiated tumor cells transplanted into mice. At
the cellular level, limiting LDH-A activity led to an increase in
the rate of oxygen consumption, which was accompanied by
a decrease in mitochondrial membrane potential. LDH-A-defi-
cient cells failed to significantly accumulate the lipophilic cation
F16, which preferentially concentrates in cells with elevated mi-
tochondrial membrane potential. Using the opposite approach,
it has been observed that acute LDH-A overexpression in pan-
creatic b cells results in an increase in mitochondrial membrane
potential (Ainscow et al., 2000). These results, like ours, highlight
the fine interplay that exists between glycolysis and mitochon-
drial metabolism. Both LDH-A and mitochondria activity are
mutually regulated at the level of metabolites. They depend on
the availability of pyruvate and on the NADH/NAD+ ratio. In the
presence of oxygen, ATP is generated by oxidation of pyruvate
in the mitochondria. Alternatively, ATP can be generated byCANCER CELL JUNE 2006
A R T I C L Econversion of glucose to lactate in the cell cytoplasm. In this
case, NADH-dependent LDH-A catalyzes the conversion of py-
ruvate into lactate. A number of factors may contribute to the
preferential funneling of pyruvate to lactate in transformed cells.
As mentioned earlier, higher levels of glycolytic enzymes and al-
terations in isoenzyme types are commonly observed in cancer
cells. Furthermore, reduced capacity to transport cytosolic
NADH into mitochondria has been reported in rapidly proliferat-
ing cells (Greiner et al., 1994). The fast kinetics of LDH-A-cata-
lyzed conversion of pyruvate into lactate ensures rapid and con-
stant supply of ATP but rapidly consumes NADH. Thus, LDH-A
regenerates NAD+ in the cytoplasm and competes with the mi-
tochondrial NADH/NAD+ shuttle systems (Golshani-Hebroni
and Bessman, 1997). The LDH-A competition for NADH is
most likely at the core of the slowdown of mitochondrial respira-
tion. In addition, as a consequence of the elevated lactate pro-
duction, the decrease in cytoplasmic pH will also impact the
efficiency of the OXPHOS chain (Conley et al., 2001). As previ-
ously proposed for proliferating T lymphocytes, it is also likely
that the overall higher rate of glycolysis causes a net increase
in the proportion of ADP bound to glycolytic enzymes. This
Figure 5. Characterization of growth properties of LDH-A-deficient tumors
Parental Neu4145, LDH-A-deficient L2-5, and complemented L2-5.c15 cells
were injected into the 4th gland mammary fat pad as described under
Experimental Procedures.
A: Kaplan-Meier survival plot for the three cohorts (ten mice per group). The
probability of survival was significantly higher for the group with tumors de-
rived from LDH-A-deficient L2-5 cells (Kaplan-Meier, chi-square = 44.96,
df = 2; log-rank p < 0.0001).
B: Kinetics of tumor growth.
C:Number of cells that scored positive for the mitotic marker Ki67, expressed
on a percent basis.
For B and C, results are expressed as average 6 SD.CANCER CELL JUNE 2006may establish a competition for the nucleotide diphosphate be-
tween these enzymes and the mitochondrial nucleotide translo-
cator ANT (Brand, 1997).
The deviation from cellular metabolic homeostasis has been
exploited for cancer diagnosis. The differential mitochondrial
membrane potential of malignant cells plays a role in the selec-
tive accumulation of cationic, lipophilic 99mTc complexes used
for tumor imaging. The heavy glucose reliance of tumor cells
constitutes the basis for tumor imaging by positron emission
tomography. These same alterations are beginning to emerge
as selective tumor traits that could provide the basis for novel
therapeutic approaches. The higher potential across the inner
mitochondrial membrane of carcinoma cells serves a selective
driving force for the accumulation of toxic delocalized lipophilic
Figure 6. Histology and characterization of LDH-A expression in tumors
A: Tumors derived from Neu4145, L2-5, and L2-5.c15 cell transplants were re-
moved at time of necropsy, fixed, and subjected to H&E staining. The smaller
size of LDH-A-deficient lesions is evident in the images on the left column
taken at identical magnification (corresponding 103magnification images
are shown on the right column). For a comparison of relative size, tumors de-
rived from Neu4145 transplants were dissected 3 weeks postinjection with
volume comparable to that of L2-5-derived tumors approximately 14 weeks
postinjection. Scale bars, 200 mm.
B: Western blot analysis of LDH-A expression of tumor whole-cell lysates pre-
pared as described under Experimental Procedures. Samples were probed
for b-actin as a loading control.431
A R T I C L Ecations like dequalinium, MKT-077, and F16 (Costantini et al.,
2000; Fantin et al., 2002; Modica-Napolitano and Aprille,
2001). The use of the anti-metabolite 2-deoxy-D-glucose to an-
tagonize the high glucose dependency of tumors has been eval-
uated in vitro as a potential novel chemotherapeutic approach
for the treatment of cancer (Aft et al., 2002). Based on the ob-
served strong LDH-A dependency for tumor proliferation from
both in vitro and in vivo studies, we propose that inhibition of
LDH-A may represent an alternative strategy toward the devel-
opment of anti-glycolytic-based therapeutic strategies for the
treatment of cancer. The tumor dependency on the glycolytic
pathway activity could arise as a consequence of genetic alter-
ations or could be a selected metabolic strategy based on
metabolite control with no underlying genetic defects. These
metabolic adaptations are essential to confer cells with full
tumorigenic potential. Our results from the in vivo experiments
demonstrate that tumors rely on glucose to lactate conversion
for growth, and that interfering with this process restricts the
ability of tumor cells to grow beyond small lesions. LDH-A activ-
ity is upregulated in tumors, and it constitutes a bottleneck for
malignant cells proliferating in the extreme tumor microenviron-
ment. Complete lack of LDH-A subunit production has been
identified in humans (Kanno et al., 1988). Individuals with hered-
itary LDH-A deficiency show myoglobinuria only after intense
anaerobic exercise (exertional myoglobinuria) but do not show
any symptoms under ordinary circumstances. Altogether, our
results and the literature suggest that antagonizing LDH-A
may be in principle achievable, tolerated, and an effective anti-
tumor approach.
Finally, the integration of information derived from genetic ap-
proaches like the one utilized here and more global small mole-
cule-based ‘‘perturbational profiling’’ strategies (Ramanathan
et al., 2005) may prove powerful in providing complementary
tools to better dissect the essential metabolic alterations that
give rise to the cancer metabolic phenotype.
Experimental procedures
Reagents
Goat polyclonal anti-LDH-A was purchased from Chemicon and anti-b-actin
from Sigma. F16 was obtained from Asinex, Hoechst 33342 from Molecular
Probes, and 2-deoxy-D-glucose from Sigma. Purified mouse monoclonal
anti-LDH-A was a generous gift of Dr. Yves Charnay (Geneva University Hos-
pitals, Geneva, Switzerland). LDH-A-derived DNA oligonucleotides encoding
shRNA were purchased from Qiagen, Inc. The pSG5 containing the human
LDH-A cDNA was obtained from Dr. Chi V. Dang’s laboratory (Johns Hopkins
University School of Medicine) and pSHAG from Dr. Gregory Hannon’s lab-
oratory (Cold Spring Harbor Laboratory).
Cell culture and generation of stable cell lines
Unless indicated, cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM), 10% FBS at 37ºC/5% CO2. For experiments performed under hyp-
oxic conditions, cells were grown in the same medium supplemented with 25
mM HEPES, in a modular chamber (Billups-Rothenberg Inc.). The gas flow
was controlled by a single flow meter (Billups-Rothenberg Inc.). The hypoxic
chamber was equilibrated with a gas mixture containing 0.5% O2/5% CO2/
94.5% N2 for 15 min prior to being sealed. NMuMg were obtained from the
ATCC. The tumor cell lines nNeu, NF980, SMF, NAF, and Neu4145 have
been established in our laboratory from mammary gland tumors dissected
from neu-transgenic mice. Immortalized, nontransformed mouse mammary
epithelial EpH4 cells were obtained from Dr. Hartmut Beug (Research Insti-
tute of Molecular Pathology, Vienna, Austria).
Stable expression of shRNAs from the U6 promoter in pSHAG-1 vector in
mouse tumor cell lines was achieved following the BseRI-BamHI protocol432(http://katahdin.cshl.org/homepage/portal/scripts/main2.pl?link=protocols
&content=protocols.html). Design of three shRNA inserts for pSHAG-1 vec-
tor, containing a 29-base stem structure complementary to the LDH-A (Gen-
bank NM_010699) was done by software found in Dr. Gregory Hannon’s
laboratory website (http://www.cshl.edu/public/SCIENCE/hannon.html).
The selected oligonucleotide sequences corresponding to nt 204–232 (L1),
nt 737–765 (L2), and nt 1161–1188 (L3) did not show significant homology
to other murine sequences as determined by BLAST. Annealed and phos-
phorylated oligonucleotides were introduced into pSHAG-1 cleaved with
BseRI and BamH1 (Paddison et al., 2002). The recombinant vector was line-
arized with EcoRV and cotransfected with pPur (Clontech) using Fugene 6
Reagent according to the manufacturer’s protocol (Roche). Selection of
stable clones was done in medium containing puromycin (1.5 mg/ml).
Proliferation assay
The effect of 2-deoxy-D-glucose on the proliferation of a panel of tumor cell
lines was assessed by BrdU incorporation assay. Neu-initiated tumor cell
lines n-Neu, NF980, SMF, NAF, and Neu4145, as well as immortalized, non-
transformed mammary epithelial cell lines EpH4 and HC11, were resus-
pended in glucose-free DMEM medium supplemented with 5% dialyzed fetal
bovine serum (90 mg/dl glucose, Invitrogen), 2 mM glucose, and 1 mM pyru-
vate. The cells were seeded in 384-well plates (2000 cells/50 ml) in the
absence or in the presence of the indicated concentration of 2-deoxy-D-glu-
cose and incubated for 36 hr. The cells were next subjected to a BrdU pulse
(20 mM for 4 hr) followed by chemiluminescent anti-BrdU immunodetection
as previously described (Fantin et al., 2002; Stockwell et al., 1999).
Determinations were done in triplicate, and the entire experiment was
repeated twice.
LDH activity assay
Total LDH-A activity was compared across clones as previously described
(Sekine et al., 1994). Briefly, 5 3 106 cells were resuspended in 500 ml assay
buffer and sonicated (setting 5, twice 5 s). Enzyme and protein assay (Brad-
ford, Bio-Rad) were performed on the supernatants obtained after centrifu-
gation at 10,0003 g for 10 min (4ºC). LDH-A activity was determined by mon-
itoring the rate of NADH (20 mM) consumption upon addition of 2 mM
pyruvate using a LS-50B spectrofluorometer (ex. 340 nm; em. 460 nm). Re-
sults from three experiments were normalized to protein content, averaged,
and in some cases expressed as percent of LDH-A activity in parental
Neu4145 cells.
Measurement of ATP
ATP levels were determined by luciferin-luciferase-based assay. Cells were
grown under normal or 0.5% O2 for 48 hr, harvested, and counted. Aliquots
containing equal number of cells were processed using the ATP Biolumines-
cence Assay kit (Roche) according to standard protocol. Measurements
were done in triplicate.
Lysate preparation and immunoblotting
Cells grown in tissue culture plates were rinsed with phosphate buffer saline
(PBS) and lysed in Laemmli sample buffer containing Complete protease in-
hibitor cocktail (Roche). DNA was sheared by sonication for 5 s on ice. Pro-
tein concentration was determined by Lowry assay (Bio-Rad). Protein lysates
were prepared from tumor samples following a simple fractionation protocol
to enrich the cell suspension for HER-2-overexpressing tumor cells. One-half
of the tumors removed were washed in Hank’s balanced salt solution,
weighed, and transferred to a plate containing DMEM (1:4 weight to volume).
Tumors were minced with flat tip tweezers and dissociated in DMEM supple-
mented with 0.15% collagenase (Roche) for 3 hr. The cell suspension was
centrifuged at 1000 rpm for 5 min in a tabletop centrifuge. The cell pellet
was washed 33 with PBS and was resuspended in an appropriate volume
of PBS/0.5% BSA that leaves 5 3 106 cells/ml. The cell suspension (0.5
ml) was incubated for 15 min on ice with 50 ml of anti-HER-2 coupled to
Dynabeads (previously prepared by incubating 10 ml of rabbit polyclonal
anti-HER2/Neu [Upstate Biotechnology] with 40 ml prewashed anti-rabbit Dy-
nabeads M-280 IgG for 2 hr on ice following standard procedure [Dynal
Biotech]). The complex (cells bound to anti-HER-2/anti-rabbit-Dynabeads)
was captured with the magnet, washed 33 with PBS, and resuspended
in 200 ml of Laemmli sample buffer. DNA was sheared by sonication as pre-
viously indicated. Protein concentration was determined by Lowry assay.CANCER CELL JUNE 2006
A R T I C L EAn aliquot of each lysate containing equivalent amounts of protein was sep-
arated by SDS-PAGE and transferred to Immobilon-P membranes (Millipore)
in buffer consisting of 25 mM Tris, 190 mM glycine, 20% methanol, 0.005%
SDS. Membranes were blocked with 1.5% BSA in TBST (150 mM NaCl, 20
mM Tris-HCl [pH 7.4], 0.3% Tween 20). Primary antibodies and secondary
antibodies were diluted in the same buffer containing 0.2% BSA. Membranes
were washed with TBST buffer and developed with horseradish peroxidase
conjugated to anti-mouse IgG (Amersham) or to anti-goat IgG (Southern Bio-
technology). The enhanced chemiluminescence reagent (Pierce) was used
for detection.
Localization of F16 in living cells
Cells were seeded in 4-well chamber slides 16 hr prior to treatment. Cells
were left untreated or were treated with 3 mM F16 for 3 hr at 37ºC. To stain
nuclei DNA, Hoechst was added to the medium (1 mg/ml; Molecular Probes)
and incubated for 30 min at 37ºC prior to imaging. The fluorescent signal of
F16 was visualized using a standard fluorescein filter set. Cells were photo-
graphed under Axioskop microscope using a Spot Camera (Diagnostic In-
struments). Magnification: 103.
Flow cytometry
The ability of cells to accumulate the fluorescent delocalized lipophilic cation
F16 (abs. 420 nm/em. 520 nm) was compared by flow cytometry. Cells were
incubated for 1 hr in medium containing 1 mM F16, harvested, washed with
PBS, resuspended in growth medium, and immediately analyzed. Measure-
ments were done in triplicate. To compare mitochondrial mass, cells were in-
cubated with the cardiolipin stain nonyl-acridine orange (NAO, Molecular
Probes). Cells were stained and analyzed as previously described (Fantin
et al., 2002). Results represent the average of two independent experiments.
Electron microscopy
Cells grown in 35 mm dishes were fixed for 1 hr at room temperature in 0.1 M
Cacodylate buffer containing 1.25% formaldehyde, 2.5% glutaraldehyde,
and 0.3% picric acid. Samples were then treated with 1% osmium tetrox-
ide/1.5% potassium ferrocyanide, followed by 1% uranyl acetate, dehy-
drated, and epon-araldite embedded. Ultrathin sections were examined
using a JEOL 1200EX microscope.
Respiration
Cells were resuspended in PBS supplemented with 25 mM glucose, 1 mM
pyruvate, and 2% BSA. Cellular respiration was measured using a Clark-
type oxygen electrode. In order to determine respiration that is used to drive
proton leak and ATP turnover, cells were incubated in the presence of oligo-
mycin (2.5 mg/106 cells). The respiration that is sensitive to oligomycin repre-
sents ATP turnover, while the respiration that is insensitive to oligomycin
indicates proton leak. Determinations were done in quadruplicate, and the
entire experiment was done twice.
Membrane potential measurements
Membrane potential measurements were carried out as described in Brand
(1995). Basically, cells were incubated for 30 min with 0.2 mCi [3H]triphenyl-
methylphosphonium (TPMP), 0.2 mM TPMP, and 1.5 mM tetraphenylboron as
carriers. To calculate membrane potential values, we used mitochondrial vol-
ume density of 8%, cell volume of 1 ml/106 cells, resting plasma membrane
potential of 269 mV, and the following TPMP binding corrections: external
medium, 0.7; cytoplasmic, 0.2; and mitochondrial, 0.4. Determinations
were done in triplicate, and the entire experiment was done twice.
Determination of NADH/NAD+ ratio
Cells grown in tissue culture plates were rinsed twice with PBS. Following ad-
dition of 1 ml of ice-cold perchloric acid (0.3 N), cells were removed with
scraper. Insoluble material was removed by centrifugation, and aliquots of
neutralized supernatant were used to measure pyruvate and lactate enzy-
matically as previously described (Bergmeyer, 1984). The free NADH/NAD+
ratios were calculated from the lactate/pyruvate ratios using the equilibrium
constant for LDH of 1.1 3 1024 (at 28ºC) and pH = 7.
Syngeneic orthotopic transplant of tumor cell lines
Parental Neu 4145 cells, as well as derived clones Neu4145 L2-5 and Neu
4145 L2-5.c15, were resuspended at 0.5 3 106 cells/100 ml in PBS andCANCER CELL JUNE 2006injected into the fourth mammary gland fat pad of 6- to 8-week-old FVB
female mice (Taconic Farms). For each cell line, a total of ten mice were
injected. Mice were followed for survival analysis. Tumors were measured
weekly with a caliper, and tumor volume was calculated using the following
formula: volume (mm3) = width23 length/2. All animal studies were approved
by the Institutional Animal Care and Use Committee (IACUC) at Harvard
Medical School. Kaplan-Meier survival plot and statistical analysis were
done with GraphPad Prism software. Statistical significance was determined
using log-rank test.
Immunohistochemistry
Tumors were dissected at time of necropsy and cut in halves. One-half was
utilized for protein lysates preparation, and the other half was rinsed in PBS
and fixed in 10% paraformaldehyde/PBS. Samples were dehydrated in 70%
ethanol, paraffin embedded, and sectioned (5 mm). Deparaffinized sections
were stained for Ki67 antigen to assess proliferation. Briefly, samples were
treated with 3% H2O2 at 220ºC for 10 min to neutralize endogenous perox-
idase activity. Sections were then blocked in 5% BSA and incubated with rat
anti-mouse Ki67 antibody (1:400 dilution; DAKO Corp.), followed by biotiny-
lated rabbit anti-mouse IgG (1:200 dilution; Vector Laboratories). Detection
was done with avidin-biotin-HRP complex (Vector laboratories) and di-ami-
nobenzidine as chromogen. Nuclei were counterstained with hematoxylin.
Ki67-positive cells were counted in four fields per tumor sample. Results
are expressed as the average 6 SD of five tumors per group.
Supplemental data
The Supplemental Data include three supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/6/425/
DC1/.
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